Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review
High‐risk non‐muscle invasive bladder cancer (NMIBC) is a common urological malignancy with a high propensity for recurrence (30–40% of patients) despite treatment with Bacillus Calmette–Guérin (BCG) instillations. Identifying patients who are likely to respond or not to BCG therapy before treatment initiation may sign...